Document:

China Oumei Real Estate Inc.: Exhibit 10.1 - Filed by newsfilecorp.com

Exhibit 10.1

AMENDMENT NUMBER 1 TO SUBSCRIPTION AGREEMENT 

THIS AMENDMENT NUMBER 1 TO SUBSCRIPTION AGREEMENT, dated as of
October 11, 2010 (this “Amendment”), is entered into by and among
China Oumei Real Estate Inc., a Cayman Islands company (the
“Company”) and the subscribers identified on the signature page
hereto (the “Majority Subscribers”). Capitalized
terms used herein but not otherwise defined herein shall have the respective
meanings set forth in the Subscription Agreement (as defined below). 

BACKGROUND 

The Company and the Subscribers (including the Majority
Subscribers) are parties to that certain Subscription Agreement, dated as of
April 14, 2010 (the “Subscription
Agreement”). The parties to this Amendment wish to
amend certain provisions of the Subscription Agreement as set forth in this
Amendment. Section 8.7 of the Subscription Agreement provides that no provision
of Section VIII (Registration Rights) of the Subscription Agreement may be
amended or waived, unless the same shall be in writing and signed by the Company
and the Holders of no less than a majority in interest of the then outstanding
Registrable Securities. This Amendment constitutes a written agreement signed by
the necessary parties in order to effectuate the amendments to the Subscription
Agreement specified below.

NOW, THEREFORE, in consideration of the foregoing and
the respective covenants and agreements set forth herein, the parties hereto
agree as follows: 

ARTICLE I 
AMENDMENTS 

SECTION 1.1. Amendment. Section 8.1 of the
Subscription Agreement is hereby deleted and the following language is hereby
inserted in its place: 

	8.1 	
      Registration; Definitions.

No later than thirty (30) days following the Closing of the
Offering (the “Filing Date”), the Company shall prepare and file with the
Commission a registration statement covering the resale of all of the Ordinary
Shares upon conversion of the outstanding shares of Preference Shares (the
“Conversion Shares”) and the Warrant Shares (collectively, the “Registrable
Securities”) on Form S-1 (or another appropriate form in accordance herewith)
(the “Registration Statement”). Subject to the terms of this Agreement, the
Company shall use its commercially best efforts to cause the Registration
Statement to be declared effective under the Securities Act as promptly as
possible after the filing thereof, but in no event later than 180 days following
the Closing of the Offering (the “Effective Date”), and shall use its
commercially reasonable efforts to keep the Registration Statement continuously
effective under the Securities Act until the date when all Registrable
Securities covered by the Registration Statement have been sold or may be sold without volume restrictions pursuant to Rule 144 as
determined by the counsel to the Company pursuant to a written opinion letter to
such effect, addressed and acceptable to the Company’s transfer agent and the
affected Holders (the “Effectiveness Period”). 

If a Registration Statement covering 100% of the Registrable
Securities is not filed with the Commission on or prior to the Filing Date or
declared effective on or prior to the Effective Date by the Commission (any such
failure or breach being referred to as an “Event,” and the date on
which such Event occurs being referred to as “Event Date”), the
Company shall reduce the initial exercise price of the Warrants issued to each
Subscriber by $0.08 per calendar month, or portion thereof, until such time as
such Registration Statement shall have been filed with the Commission or
declared effective by the Commission, as the case may be. For the avoidance of
doubt, in no event will the Company be obligated to reduce the initial exercise
price of the Warrants issued to each Subscriber under this Agreement in excess
of $0.80 in aggregate. The partial reduction of the initial exercise price of
the Warrants pursuant to the terms hereof shall apply on a daily pro-rata basis
for any portion of a calendar month prior to the cure of an Event (except in the
case of the first Event Date), and shall cease to accrue (unless earlier cured)
upon the expiration of the Effectiveness Period. 

The securities shall only be treated as Registrable Securities
if and only for so long as they (i) have not been sold (A) pursuant to a
registration statement; (B) to or through a broker, dealer or underwriter in a
public distribution or a public securities transaction; and/or (C) in a
transaction exempt from the registration and prospectus delivery requirements of
the Securities Act under Section 4(1) thereof so that all transfer restrictions
and restrictive legends with respect thereto, if any, are removed upon the
consummation of such sale; (ii) are not held by a Holder or a permitted
transferee; and (iii) are not eligible for sale pursuant to Rule 144 (or any
successor thereto) under the Securities Act.

The term “Holder” shall mean any person owning or having the
right to acquire Registrable Securities or any permitted transferee of a Holder.

SECTION 1.2. Full Force and Effect. For the
avoidance of doubt, all other provisions of the Subscription Agreement shall
remain in full force and effect. 

ARTICLE II 
MISCELLANEOUS 

SECTION 2.1. Governing Law. This Amendment shall
be governed by and construed in accordance with the laws of the State of New
York. 

SECTION 2.2. Entire Agreement. This Amendment
along with the Subscription Agreement contains the entire understanding of the
parties with respect to the subject matter hereof and supersedes all prior
agreements, understandings, discussions and
representations, oral or written, with respect to such matters, which the parties acknowledge have been merged into this Amendment. 

SECTION 2.3. Counterparts. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK] 

 

 

IN WITNESS WHEREOF, the parties hereto have caused this
Amendment to be duly executed by their respective authorized signatories as of
the date first indicated above. 

COMPANY:

CHINA OUMEI REAL ESTATE INC.

By: /s/ Weiqing
Zhang                                           

Name: Weiqing Zhang 
Title: Chief Executive Officer 

MAJORITY SUBSCRIBERS: 

ACCESS AMERICA FUND, LP 

By: /s Christopher
Efird                                           

Name: Christopher Efird 
Title: President

HUA-MEI 21ST CENTURY PARTNERS, LP 

By: /s/ Peter
Siris                                                      

Name: Peter Siris 
Title: Managing Director

GUERRILLA PARTNERS, LP 

By: /s/ Peter
Siris                                                      

Name: Peter Siris 
Title: Managing Director

TAYLOR INTERNATIONAL FUND, LTD. 

By: /s/ Stephen Taylor                                              

Name: Stephen Taylor
Title: Partnerf8k10610ex10i_amenrgyfields.htm

Exhibit 10.1

 

AMERICAN ENERGY FIELDS, INC.

3266 W. Galveston Dr. #101

Apache Junction, AZ 85120

 

October 6, 2010

 

Mr. Bill Allred

Post Office Box 1141 

232 East 300 South 

Pima, Arizona 85543

 

Dear Mr. Allred,

 

This letter sets forth the principal terms and conditions governing your role as an independent director of American Energy Fields, Inc. (the "Company"). The principal terms and conditions are as follows:

 

	 	1.	Independent Director: You shall serve as an independent director of the Company.
	 	 	 
	 	2.	Committees: You shall serve as a chairman and/or member of board committees as such committees are from time to time constituted.
	 	 	 
	 	3.	Equity: You shall receive an aggregate of 150,000 stock options with an exercise price of $0.25 per share. 30,000 such options shall vest on the six-month anniversary of this letter and on each six-month anniversary thereafter (each, an "Option Payment"), for a total vesting period of thirty (30) months.

 

The parties intend that this letter constitute a binding agreement between them.

 

If the foregoing terms are acceptable to you, please indicate you acceptance and agreement with the Company by executing this letter in the space below provided for that purpose, and returning such copy at your earliest convenience.

 

Sincerely,

 

 

American Energy Fields, Inc.

 

	
By: 

	/s/ Joshua Bleak	 
	 	Joshua Bleak, President	 
	 	 	 
	 	 	 
	 	/s/ Bill Allred	 
	 	Bill Allredf8k10610ex10i_dongsheng.htm

Exhibit 10.1

 

DIRECTOR AGREEMENT

This DIRECTOR AGREEMENT is made as of this 6th day of October, 2010 (the “Agreement”), by and between Dongsheng Pharmaceutical International Co., Ltd., a Delaware corporation (the “Company”) and Robert Adler (the “Director”).

WHEREAS, the Company appointed the Director as a member of the Board of Directors of the Company on October 6th, 2010 and desires to enter into an agreement with the Director with respect to such appointment; and

WHEREAS, the Director is willing to accept such appointment and to serve the Company on the terms set forth herein, and in accordance with, the provisions of this Agreement.

NOW, THEREFORE, in consideration of the mutual covenants contained herein, the parties hereto agree as follows:

1. Position.  Subject to the terms and provisions of this Agreement, the Company shall cause the Director to be appointed as a non-executive member of the board of directors of the Company (the “Board”) and the Director hereby agrees to serve the Company in that position upon the terms and conditions hereinafter set forth, provided, however, that the Director’s continued service on the Board after the initial one-year term on the Board shall be subject to any necessary approval by the Company’s stockholders.

2. Duties.  During the Directorship Term (as defined in Section 5 hereof), the Director shall serve as a member of the Board, and the Director shall make reasonable business efforts to attend all Board meetings, serve on appropriate subcommittees as reasonably requested by the Board, make himself available to the Company at mutually convenient times and places, attend external meetings and presentations, as appropriate and convenient, and perform such duties, services and responsibilities and have the authority commensurate to such position.

The Director will use his best efforts to promote the interests of the Company. The Company recognizes that the Director (i) is or may become a full-time executive employee of another entity and that his responsibilities to such entity must have priority and (ii) sits on the board of directors of other entities.  Notwithstanding the same, the Director will use reasonable business efforts to coordinate his respective commitments so as to fulfill his obligations to the Company and, in any event, will fulfill his legal obligations as a director. Other than as set forth above, the Director will not, without the prior notification to the Board, engage in any other business activity which could materially interfere with the performance of his duties, services and responsibilities hereunder or which is in violation of the reasonable policies established from time to time by the Company, provided that the foregoing shall in no way limit his activities on behalf of (i) his current employer and its affiliates or (ii) the board of directors of those entities on which he sits.  At such time as the Board receives such notification, the Board may require the resignation of the Director if it determines that such business activity does in fact materially interfere with the performance of the Director’s duties, services and responsibilities hereunder.

3. Board Committees. The Director hereby agrees to serve as the Chairman of the Audit Committee of the Board and to perform all of the duties, services and responsibilities necessary thereunder.

4. Monetary Remuneration.

 

  

1

  

 

(a) Fees and Compensation.  During the Directorship Term the Director shall receive the following compensation and benefits:

(i) A cash payment of $12,000.00 per year to be paid quarterly in equal installments commencing from October 6, 2010.

(ii) 30,000 stock options, such options to vest pursuant to the following schedule: (A) 10,000 stock options to vest on October 6, 2011; (B) 10,000 of stock options to vest on October 6, 2012, which is contingent upon the renewal of this agreement from October 6, 2011 to October 6, 2012; and (C) 10,000 stock options to vest on October 6, 2013, which is contingent upon the renewal of this agreement from October 6, 2012 to October 6, 2013.

(iii) The Director’s status during the Directorship Term (as defined herein) shall be that of an independent contractor and not, for any purpose, that of an employee or agent with authority to bind the Company in any respect. All payments and other consideration made or provided to the Director under Section 4 shall be made or provided without withholding or deduction of any kind, and the Director shall assume sole responsibility for discharging, all tax or other obligations associated therewith.

(b) Expense Reimbursements.  During the Directorship Term, the Company shall reimburse the Director for all reasonable out-of-pocket expenses incurred by the Director in attending any in-person meetings, provided that the Director complies with the generally applicable policies, practices and procedures of the Company for submission of expense reports, receipts or similar documentation of such expenses. Any reimbursements for allocated expenses (as compared to out-of-pocket expenses of the Director) must be approved in advance by the Company.

5. Directorship Term.  The “Directorship Term,” as used in this Agreement, shall mean the period commencing on October 6, 2010 and terminating on the 6th day of October, 2011, or the earliest of the following to occur:

(a) the death of the Director;

(b) the termination of the Director from the position of member of the Board by the mutual agreement of the Company and the Director;

(c) the removal of the Director from the Board by the shareholders of the Company;

(d) the resignation by the Director from the Board if, after the date hereof, the chief executive officer of his current employer determines that the Director’s continued service on the Board conflicts with his fiduciary obligations to his current employer (a “Fiduciary Resignation”); and

(e) the resignation by the Director from the Board if the board of directors or the chief executive officer of his current employer requires the Director to resign and such resignation is not a Fiduciary Resignation.

6. Director’s Representation and Acknowledgment.  The Director represents to the Company that his execution and performance of this Agreement shall not be in violation of any agreement or obligation (whether or not written) that he may have with or to any person or entity, including without limitation, any prior employer. The Director hereby acknowledges and agrees that this Agreement (and any other agreement or obligation referred to herein) shall be an obligation solely of the Company, and the Director shall have no recourse whatsoever against any stockholder of the Company or any of their respective affiliates with regard to this Agreement.

 

  

2

  

 

7. Director Covenants.

(a) Unauthorized Disclosure.  The Director agrees and understands that in the Director’s position with the Company, the Director has been and will be exposed to and receive information relating to the confidential affairs of the Company, including but not limited to technical information, business and marketing plans, strategies, customer information, other information concerning the Company’s products, promotions, development, financing, expansion plans, business policies and practices, and other forms of information considered by the Company to be confidential and in the nature of trade secrets. The Director agrees that during the Directorship Term and thereafter, the Director will keep such information confidential and will not disclose such information, either directly or indirectly, to any third person or entity without the prior written consent of the Company; provided, however, that (i) the Director shall have no such obligation to the extent such information is or becomes publicly known or generally known in the Company’s industry other than as a result of the Director’s breach of his obligations hereunder and (ii) the Director may, after giving prior notice to the Company to the extent practicable under the circumstances, disclose such information to the extent required by applicable laws or governmental regulations or judicial or regulatory process. This confidentiality covenant has no temporal, geographical or territorial restriction. Upon termination of the Directorship Term, the Director will promptly return to the Company all property, keys, notes, memoranda, writings, lists, files, reports, customer lists, correspondence, tapes, disks, cards, surveys, maps, logs, machines, technical data or any other tangible product or document which has been produced by, received by or otherwise submitted to the Director in the course or otherwise as a result of the Director’s position with the Company during or prior to the Directorship Term, provided that, the Company shall retain such materials and make them available to the Director if requested by his in connection with any litigation against the Director under circumstances in which (i) the Director demonstrates to the reasonable satisfaction of the Company that the materials are necessary to his defense in the litigation and (ii) the confidentiality of the materials is preserved to the reasonable satisfaction of the Company.

(b) Non-Solicitation.  During the Directorship Term and for a period of three (3) years thereafter, the Director shall not interfere with the Company’s relationship with, or endeavor to entice away from the Company, any person who, on the date of the termination of the Directorship Term, was an employee or customer of the Company or otherwise had a material business relationship with the Company.

(c) Remedies.  The Director agrees that any breach of the terms of this Section 7 would result in irreparable injury and damage to the Company for which the Company would have no adequate remedy at law; the Director therefore also agrees that in the event of said breach or any threat of breach, the Company shall be entitled to an immediate injunction and restraining order to prevent such breach and/or threatened breach and/or continued breach by the Director and/or any and all entities acting for and/or with the Director, without having to prove damages, in addition to any other remedies to which the Company may be entitled at law or in equity. The terms of this paragraph shall not prevent the Company from pursuing any other available remedies for any breach or threatened breach hereof, including but not limited to the recovery of damages from the Director. The Director acknowledges that the Company would not have entered into this Agreement had the Director not agreed to the provisions of this Section 7.

(i) The provisions of this Section 7 shall survive any termination of the Directorship Term, and the existence of any claim or cause of action by the Director against the Company, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement by the Company of the covenants and agreements of this Section 7.

 

  

3

  

 

8. Indemnification.  The Company agrees to indemnify the Director for his activities as a director of the Company to the fullest extent permitted by law, and to cover the Director under any directors and officers liability insurance obtained by the Company.  The Company agrees to maintain a directors and officers liability insurance policy with a minimum coverage of $5 million.

9. Non-Waiver of Rights.  The failure to enforce at any time the provisions of this Agreement or to require at any time performance by the other party of any of the provisions hereof shall in no way be construed to be a waiver of such provisions or to affect either the validity of this Agreement or any part hereof, or the right of either party to enforce each and every provision in accordance with its terms. No waiver by either party hereto of any breach by the other party hereto of any provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions at that time or at any prior or subsequent time.

10. Notices.  Every notice relating to this Agreement shall be in writing and shall be given by personal delivery or by registered or certified mail, postage prepaid, return receipt requested; to:

If to the Company:

Dongsheng Pharmaceutical International Co., Ltd.

China Bing’qi Plaza, Floor 17, No 69,

Zi Zhu Yuan Rd, Hai’dian District, Beijing

People’s Republic of China 100089

Telephone: +86-10-88580708

With a copy to:

 

 

Joseph M. Lucosky

Anslow & Jaclin, LLP

195 Route 9 South, Suite 204

Manalapan, NJ 07726

Telephone: (732) 409-1212

If to the Director:

Robert Adler

23 Driftwood Drive

Port Washington, NY 11050

Either of the parties hereto may change their address for purposes of notice hereunder by giving notice in writing to such other party pursuant to this Section 10.

11. Binding Effect/Assignment.  This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective heirs, executors, personal representatives, estates, successors (including, without limitation, by way of merger) and assigns. Notwithstanding the provisions of the immediately preceding sentence, neither the Director nor the Company shall assign all or any portion of this Agreement without the prior written consent of the other party.

 

  

4

  

 

12. Entire Agreement.  This Agreement (together with the other agreements referred to herein) sets forth the entire understanding of the parties hereto with respect to the subject matter hereof and supersedes all prior agreements, written or oral, between them as to such subject matter.

13. Severability.  If any provision of this Agreement, or any application thereof to any circumstances, is invalid, in whole or in part, such provision or application shall to that extent be severable and shall not affect other provisions or applications of this Agreement.

14. Governing Law.  This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without reference to the principles of conflict of laws. All actions and proceedings arising out of or relating to this Agreement shall be heard and determined in any court in the State of Delaware and the parties hereto hereby consent to the jurisdiction of such courts in any such action or proceeding; provided, however, that neither party shall commence any such action or proceeding unless prior thereto the parties have in good faith attempted to resolve the claim, dispute or cause of action which is the subject of such action or proceeding through mediation by an independent third party.

15. Legal Fees.  The parties hereto agree that the non-prevailing party in any dispute, claim, action or proceeding between the parties hereto arising out of or relating to the terms and conditions of this Agreement or any provision thereof (a “Dispute”), shall reimburse the prevailing party for reasonable attorney’s fees and expenses incurred by the prevailing party in connection with such Dispute; provided, however, that the Director shall only be required to reimburse the Company for its fees and expenses incurred in connection with a Dispute, if the Director’s position in such Dispute was found by the court, arbitrator or other person or entity presiding over such Dispute to be frivolous or advanced not in good faith.

16. Modifications.  Neither this Agreement nor any provision hereof may be modified, altered, amended or waived except by an instrument in writing duly signed by the party to be charged.

17. Tense and Headings.  Whenever any words used herein are in the singular form, they shall be construed as though they were also used in the plural form in all cases where they would so apply. The headings contained herein are solely for the purposes of reference, are not part of this Agreement and shall not in any way affect the meaning or interpretation of this Agreement.

18. Counterparts.  This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument.

 

 

[-Signature Page Follows-]

 

  

5

  

 

IN WITNESS WHEREOF, the Company has caused this Director Agreement to be executed by authority of its Board of Directors, and the Director has hereunto set his hand, on the day and year first above written.

Dongsheng Pharmaceutical International Co., Ltd.

By:      /s/ Xiaodong Zhu                                 

Name:     Xiaodong Zhu

Title:       Chief Executive Officer

Independent Director

By: /s/ Robert Adler                                       

Name: Robert Adler

 

 

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00179-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00179-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00179-of-00352.parquet"}]]